Т786С POLYMORPHISM IN THE ENDOTHELIAL NO SYNTHASE GENE, VASCULAR ENDOTHELIAL GROWTH FACTOR-А IN MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION
PDF (Українська)

Keywords

STEMI, polymorphism Т786С in the endothelial NO-synthase gene, VEGF-А

How to Cite

Petyunina, O. V., Kopytsya, M. P., & Pietienova, L. L. (2019). Т786С POLYMORPHISM IN THE ENDOTHELIAL NO SYNTHASE GENE, VASCULAR ENDOTHELIAL GROWTH FACTOR-А IN MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION. Eastern Ukrainian Medical Journal, 7(1), 48-59. Retrieved from https://eumj.med.sumdu.edu.ua/index.php/journal/article/view/8

Abstract

Purpose. To investigate associations of polymorphism Т786С in the eNOS gene with clinical and anamnestic data in patients with ST-segment elevation myocardial infarction (STEMI), the level of vascular endothelial growth factor-A (VEGF-А), clinical course and prognosis of disease.

Material and methods. 177 patients with STEMI (139 (78.5%) were male and 38 (21.5%) were female with the average age of (61.73±9.44) years) admitted to intensive care unit of GI “L. T. Malaya Therapy National Institute of AMS of Ukraine” between January 2016 and July 2018 were investigated. Polymerase chain reaction was used to determine allele polymorphism T786C of eNOS gene. Serum level of VEGF by enzyme-linked immunosorbent assay (IBL INTERNATIONAL GMBH, Germany) was determined. After a 6-month observation period combined endpoints (afterinfarction angina, chronic heart failure, cardiovascular death) were assessed.

Results. STEMI originated 2.58 times more often in the carriers of 786CC-genotype of eNOS gene in presence of diabetes mellitus type 2 (95% OR (1.10–5.88)), 2.28 times more often in smokers (95% OR (1.03–4.88)), 2.28 times more often – under 55 years (95% OR (1.03–4.88)), 3.03 times more often – in patients with unstable angina before event. Polymorphism 786СС in the eNOS gene was an independent predictor of unfavorable course of postinfarction period (afterinfarction angina, chronic heart failure, cardiovascular death) during 6-month observation period (Р = 0.0029). VEGF-А level increased in the carriers of 786ТТ-genotype of eNOS gene polymorphism with STEMI, and low level was observed in patients with minor 786CC-genotype. These data testifies to possible genetic determinant between VEFG-A level and eNOS gene polymorphism.

Conclusion. Observed findings may show new approach to stratification of patients for unfavorable duration of postinfarction period.

PDF (Українська)

References

1. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010 May;459(6):923–39. doi: 10.1007/s00424-010-0808-2. Epub 2010 Mar 21.
2. Titov VN. Anatomicheskie i funktsionalnyie osnovyi endoteliy-zavisimoy vazodilatatsii, oksid azota i endotelin. Rossiyskiy kardiologicheskiy zhurnal. 2008; 1(69):71-75.
3. Marsden PA, Heng HH, Scherer SW. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;268:17478– 17488
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002– 2012.
5. Karantzoulis-Fegaras F, Antoniou H, Lai SL. Characterization of the human endothelial nitric-oxide synthase promoter. J Biol Chem 1999;274:3076–3093.
6. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, et al. T−786!C Mutation in the 50 -Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm. Circulation. 1999; 99: 2864–2870. PMID: 10359729 24.
7. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K, et al. T(-786)—> C mutation in the 5’-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000; 86: 628–634. PMID: 10980213
8. Dosenko VIe, Lutai YaM, Parkhomenko AN Alelnyi polimorfizm endotelialnoi NO-syntazy promotora T (-786)S hena yak faktor ryzyku hostroho koronarnoho syndromu. Fiziolohiia. 2005; 51(1):72-76 (in Ukr)
9. Dosenko VIe Rol alelnoho polimorfizmu heniv endotelialnoi NO-syntazy ta proteasomy v patohenezi sertsevo-sudynnykh zakhvoriuvan: molekuliarno-henetychni aspekty: Avtoref.dys. d-ra med.nauk. –K., 2006 (in Ukr).
10. Parhomenko AN, Irkin OI, Lutay YaM i soavt. Endotelialnaya disfunktsiya u bolnyih s ostryim infarktom miokarda: svyaz s techeniem zabolevaniya. Ukr Kardiol Zhurnal. 2013; 4 (Dodatok):165-166 (in Russ).
11. Parhomenko AN, Lutay YaM, Irkin OI, Kozhuhov SN, Skarzhevskiy AA Kliniko-prognosticheskoe znachenie polimorfizma gena endotelialnoy NO-sintetazyi u bolnyih s ostryimi koronarnyimi sindromami. Meditsina neotlozhnyih sostoyaniy. 2014; 3(58):45-54 (in Russ)
12. Tseluiko VI, Yakovleva LM Polimorfizm heniv endotelialnoi NO-syntazy, anhiotenzynperetvoriuiuchoho fermentu ta retseptora anhiotenzynu II typu 1 u khvorykh na ishemichnu khvorobu sertsia z arterialnoiu hipertenziieiu. Arteryalnaia hypertenzyia. 2013. 6(32):28-33 (in Ukr).
13. Tseluiko VI, Yakovleva LM, Matuzok OE Kliniko-anamnestychna kharakterystyka ta pokaznyky vnutrishnosertsevoi hemodynamiky u khvorykh z hostrym infarktom miokarda zalezhno vid polimorfizmu T(-786)С hena endotelialnoi NO-syntazy. Sertse i sudyny. 2017; 2:46-52.
14. Nakayama M, Yoshimura M, Sakamoto T, Shimasaki Y, Nakamura S, Ito T, Abe K, et al. Synergistic interaction of T-786-->C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm Pharmacogenetics. 2003; 13(11):683-8. DOI:10.1097/01.fpc.0000054134.14659.2c
15. Çiftçi C, Melil S, Çebi Y, Ersöz M, Çağatay P et al. Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart diseaseLipids in Health and Disease2008; 7:5 https://doi.org/10.1186/1476-511X-7-5
16. Jo I, Moon J, Yoon S, Kim H-T, Kim E, Park H-Y, et al. Interaction between -786TC polymorphism in the endothelial nitric oxide synthase gene and smoking for myocardial infarction in Korean population. Clin Chim Acta Int J Clin Chem. 2006; 365: 86–92.
17. Kim IJ, Bae J, Lim SW, Cha DH, Cho HJ, Kim S, et al. Influence of endothelial nitric oxide synthase gene polymorphisms (-786T>C, 4a4b, 894G>T) in Korean patients with coronary artery disease. Thromb Res. 2007; 119: 579–585. doi: 10.1016/j.thromres.2006.06.005 PMID: 16842840
18. Kong XZ, Zhang ZY, Wei L-H, Li R, Yu J The Endothelial Nitric Oxide Synthase Gene T-786C Polymorphism Increases Myocardial Infarction Risk: A Meta-Analysis Med Sci Monit 2017; 23:759-766. DOI: 10.12659/MSM.899905
19. Xu ZX, Li GQ: Association between endothelial nitric ocide synthase gene786T/C polymorphism and myocardial infarction in Xinjiang Uygur and Han population. Journal of Chinese Practical Diagnosis and Therapy, 2013; 27: 753–55
20. Zigra AM, Rallidis LS, Anastasiou G, Merkouri E, Gialeraki A. eNOS gene variants and the risk of premature myocardial infarction. Dis Markers. 2013; 34(6):431-6. doi: 10.3233/DMA-130987.
21. Arun Kumar AS, Umamaheswaran G, Padmapriya R, Balachandar J, Adithan C. Endothelial nitric oxide synthase gene polymorphisms and the risk of acute myocardial infarction in a South Indian population. Mol Biol Rep. 2013 Feb;40(2):1275-81. doi: 10.1007/s11033-012-2170-2. Epub 2012 Oct 29.
22. Da Costa Escobar Piccoli J, Manfredini V, Hamester FI, Bandinelli JB, Turkienicz IM, Chies JA, Peres A, Bodanese LC, Bogo MR. Interaction between endothelial nitric oxide synthase gene polymorphisms (-786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes. Arch Med Res. 2012 Apr;43(3):205-11. doi: 10.1016/j.arcmed.2012.03.011. Epub 2012 Apr 1.
23. Kallel A, Sbaï MH, Sediri Y, Abdessalem S, Mourali MS, Feki M, Mechmeche R, Jemaa R, Kaabachi N. Polymorphisms of the NOS3 gene and risk of myocardial infarction in the Tunisian population. Cytokine. 2013 Dec;64(3):646-51. doi: 10.1016/j.cyto.2013.09.005. Epub 2013 Oct 3.
24. Berezin AE Predicitive role of circulating vascular endothelial growth factor-1 in patients with cardiovascular diseases. J Dis Markers. 2014; 1(3): id1013.
25. Gavrilenko TI, Ryzhkova NA, Parchomenko AN. Vessel endothelial growth factor in the clinic of internal diseases. Its pathogenetic role. Ukrainian Cardiologic Journal. 2011; 4:P.87-95 (in Rus).
26. Hoeben A, Landuyt B, Highley MS et al. Vascular endothelial growth factor and angiogenesis. Pharmacological Rewiews. 2004; 56(4): 549-580. Doi:10.1124/pr.56.4.3.
27. Starostin I.V., Talitskiy K.A., Bulkina O.S., Parfenova E.V., Karpov Yu.A. Kollateralnyiy krovotok v miokarde: rol faktora rosta endoteliya sosudov. Kardiologiya. 2012; 11:49-55 (in Russ).
28. Kimura K., Hashiguchi T., Deguchi T. et al. Serum VEGF – as a prognostic factor of atherosclerosis. Atherosclerosis. 2007; 194(1):182-188. DOI:10.1016/j.atherosclerosis.2006.07.025
29. Roslavtseva VV, Salmina AB, Prokopenko SV et al. The role of vascular endothelial growth factor in the regulation of development and functioning of the brain: new target molecules for pharmacotherapy. Biomedicinskaia chimiia. 2016; 62(2): 124-133. Doi:10.1809/PBMC20166202124 (in Russ).
30. Devaux Y, Vausort M, Azuaje F et al. Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction. J Card Fail. 2012; 18(4):P.330-337. Doi: 10.1016/j.cardfail.2012.01.010.
31. Hojo Y, Ikeda U, Zhu Y et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol. 2000; 35(4): 968-973. PMID: 10732896
32. Shimokawahara H, Jougasaki M, Setoguchi M et al. Relationsheep between vascular endothelial growth factor and left ventricular dimension in patients with acute myocardial infarction. J Cardiol. 2014; 64(5): 360-365. Doi: 10.1016/j.jjcc.2014.02.017
33. Pieper GM: Enhanced, unaltered and impaired nitric oxide-mediated endothelium dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia. 1999; 42:204–213
34. Doshi AA, Ziolo MT, Wang H, Burke E, Lesinski A, Binkley P. A promoter polymorphism of the endothelial nitric oxide synthase gene is associated with reduced mRNA and protein expression in failing human myocardium. J Card Fail. 2010 Apr;16(4):314-9. doi: 10.1016/j.cardfail.2009.12.013. Epub 2010 Feb 7.
35. Gururajan P, Gurumurthy P, Victor D, Srinivasa Nageswara Rao G, Sai Babu R, et al. (2011) Plasma total nitric oxide and endothelial constitutive nitric oxide synthase (ecNOS) gene polymorphism: a study in a South Indian population. Biochem Genet 49(1-2): 96–103.
36. Salimi S, Naghavi A, Firoozrai M, Zandd H, Tavilani H, et al. Association of plasma nitric oxide concentration and endothelial nitric oxide synthase T-786C gene polymorphism in coronary artery disease. -2012. Pathophysiology 19(3): 157-162.
37. Yakovleva LM. Polimorfizm heniv endotelialnoi NO-syntazy, anhiotenzynperetvoriuiuchoho fermentu ta retseptora anhiotenzynu 2 typu 1 u khvorykh na ishemichnu khvorobu sertsia z tsukrovym diabetom II typu. Medychni perspektyvy. 2013; XVIII/4:45-52.
38. Wang J, Dudley D, Wang XL Haplotype-Specific Effects on Endothelial NO Synthase Promoter Efficiency Modifiable by Cigarette Smoking. Arterioscler Thromb Vasc Biol. 2002 May 1; 22(5): e1–e4. doi: 10.1161/01.ATV.0000016248.51577.1F
39. Zadionchenko VS, Leksina KS, Timofeeva NYu i soavt. Vliyanie ingibitora APF na oksidativnyiy stress, funktsiyu endoteliya u bolnyih infarktom miokarda. Kardiologiya. 2009; 708:32-37. (in Russ)
40. Chintalgattu V, Nair DM, Katwa LC. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J Mol Cell Cardiol. 2003 Mar; 35(3):277-86. PubMed PMID: 12676542.
41. Taimeh Z, Loughran J, Birks EJ, Bolli R. Vascular endothelial growth factor in heart failure. Nat Rev Cardiol. 2013 Sep;10(9):519-30. doi: 10.1038/nrcardio.2013.94. Epub 2013 Jul 16.
42. Han Y, Xu W, Zhang W, Liu N, Ji Y. T-786C polymorphism in the endothelial nitric oxide synthase gene is associated with increased risk of coronary artery disease in a Chinese population. Pharmacology. 2010; 85: 211–216. doi: 10.1159/000275135 PMID: 20215811
43. Matsudaira K, Maeda K, Okumura N, Yoshikawa D, Morita Y, Mitsuhashi H, et al. Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month outcome. Resuls from Nagoya Acute Myocardial Infarction Study. Circ J. 2012; 76:1509-16. DOI: 10.1253/circj.CJ-11-1127.
44. Niu W, Qi Y. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One. 2011; 6(9):e24266. doi: [10.1371/journal.pone.0024266]
45. Niu J, Han X, Qi H, Yin J, Zhang Z, Zhang Z. Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction. Exp Ther Med. 2016;12(1):475-479. DOI: 10.3892/etm.2016.3286
46. Teplyakov AT, Berezikova EN, Shilov SN, Grakova EV, Torim YuYu, Efremova AV i soavt. Patogeneticheskaya i prognosticheskaya znachimost rostovyih faktorov v razvitii hronicheskoy serdechnoy nedostatochnosti. Kardiologiya. 2017; 57(10):20–28. DOI: 10.18087/cardio.2017.10.10039
47. Petyunina OV, Kopytsya MP, Kuznetsov IV, Vyshnevska IR Prognostication of clinical outcomes after STEMI: the role of vascular endothelial growth factor Georgian medical news : 2018; 6 (279):79-86
48. Petyunina OV, Kopytsya MP Asotsiatsii rivnia vaskuloendotelialnoho faktora rostu A z pokaznykamy hemodynamiky u khvorykh, shcho perenesly infarkt miokarda z elevatsiieiu sehmenta ST. Ukrainskyi kardiolohichnyi zhurnal. 2018; 5:45-54. Doi: http://doi.org/10/31928/1608-635X-2018.5.4553.